ClinicalTrials.gg
TerminatedNCT03071692PROMINENTUpdated Sep 25, 2025Results posted

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

A Phase 3 interventional study of K-877 and Placebo in Type2 Diabetes and Dyslipidemia, sponsored by Kowa Research Institute, Inc.. Terminated at 888 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-25.

Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 3, Interventional, and Prevention

Why this study was terminated
The study was stopped for futility based on efficacy results at the interim analysis; no unexpected safety findings were observed.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10,544
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Dyslipidemias by Kowa Company, Ltd. — none open to participants now, none under way, none of them phase 3. Dyslipidemias · Kowa Company, Ltd..

Enrollment
Largest of 20
10,544 · median 290
Started
2017
the only one that year
Phase 3
14 of 20
none open now
Registered
16th of 20
by date

Among the 20 studies in Dyslipidemias by Kowa Company, Ltd., this one has the largest enrollment, is the only one that started in 2017, is one of 14 in phase 3, and was the 16th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 20 studies in Dyslipidemias by Kowa Company, Ltd. is open now. The open studies under Dyslipidemias, anywhere →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Dyslipidemias by Kowa Company, Ltd. as a file.
02

Study summary

The primary objective of the study is to determine whether pemafibrate administered twice daily will delay the time to first occurrence of any component of the clinical composite endpoint of:

  • nonfatal Myocardial Infarction (MI)
  • nonfatal ischemic stroke
  • coronary revascularization; or
  • Cardio Vascular (CV) death.
Read the detailed description

A multi-regional clinical trial with participating sites in the following countries. India is being conducted under a previous protocol version due to regulatory requirements.

  • Argentina
  • Brazil
  • Bulgaria
  • Canada
  • Colombia
  • Czech Republic
  • Denmark
  • France
  • Germany
  • Hungary
  • India
  • Israel
  • Japan
  • Mexico
  • Netherlands
  • Poland
  • Romania
  • Russian Federation
  • Slovakia
  • South Africa
  • Spain
  • Ukraine
  • United Kingdom
  • United States
03

Conditions studied

  • Type2 Diabetes
  • Dyslipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fasting TG ≥ 200 mg/dL (2.26 mmol/L) and \< 500 mg/dL (5.65 mmol/L) at Visit 1 (Screening/Enrollment Visit) or Visit 1.1 (Retest)
  2. HDL-C ≤ 40 mg/dL (1.03 mmol/L) at Visit 1 (Screening/Enrollment Visit) or Visit 1.1 (Retest)
  3. Type 2 diabetes of longer than 12 weeks duration documented in medical records, for example: local laboratory evidence through medical record review of elevated (≥ 6.5% [48 mmol/mol]), elevated plasma glucose (fasting ≥ 126 mg/dL [7.0 mmol/L], 2-hour ≥ 200 mg/dL [11.1 mmol/L] during oral glucose tolerance testing, or random value ≥ 200 mg/dL with classic symptoms, or currently taking medication for treatment of diabetes; AND either

    1. Age ≥ 50 years if male or ≥ 55 years if female (primary prevention cohort); OR
    2. Age ≥ 18 years and established systemic atherosclerosis (secondary prevention cohort), defined as any 1 of the following:

      • i. Prior MI or ischemic (non-hemorrhagic) stroke
      • ii. Coronary angiographic lesion of ≥ 60% stenosis in a major epicardial vessel or ≥ 50% left main stenosis
      • iii. Asymptomatic carotid disease with ≥ 70% carotid artery stenosis
      • iv. Symptomatic carotid disease with ≥ 50% carotid artery stenosis
      • v. Symptomatic lower extremity PAD (ie, intermittent claudication, rest pain, lower extremity ischemic ulceration, or major amputation with either ankle-brachial index ≤ 0.9 or other diagnostic testing [eg, toe-brachial index, angiogram, or other imaging study])
      • vi. Prior arterial revascularization procedure (including coronary, carotid, or peripheral angioplasty/stenting, bypass, or atherectomy/endarterectomy)

Exclusion criteria

Exclusion Criteria:

  1. Current or planned use of fibrates or agents with PPAR-α agonist activity (eg, saroglitazar) within 6 weeks (42 days) of Visit 1 (Screening/Enrollment Visit). Note: PPAR-γ agonists (eg, glizatones such as pioglitazone and rosiglitazone) are allowed
  2. Known sensitivity to PPAR-α agonists or tablet
  3. Initiation of, or change in, current TG-lowering therapy within 12 weeks of Visit 1 (if applicable). Note: TG-lowering therapy is defined as niacin > 100 mg/day or dietary supplements or prescription omega-3 fatty acids > 1 g/day
  4. Type 1 diabetes mellitus
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
10,544 participants (actual)

Study arms

  • Experimental
    Treatment Group

    K-877 (pemafibrate) tablet twice daily.

    Drug: K-877

  • Placebo comparator
    Control Group

    Matching K-877 placebo tablet twice daily.

    Drug: Placebo

Interventions

  • DrugK-877

    0.2mg tablet

    Also known as: pemafibrate

  • DrugPlacebo

    K-877 matching placebo tablet

06

What researchers measure

Primary outcomes

  1. Number of Participants With First Occurrence of 4-component Composite Primary Endpoint (Nonfatal MI, Nonfatal Ischemic Stroke, Coronary Revascularization, or CV Death)

    Number of participants experiencing their first occurrence of any component of the 4-component composite primary endpoint, which includes nonfatal myocardial infarction (MI), nonfatal ischemic stroke, coronary revascularization, or cardiovascular (CV) death. Each participant is counted only once, regardless of any subsequent events.

    Time frame: From Baseline to a Median of 3.3 Years

Secondary outcomes

  1. Number of Participants With First Occurrence of the 4-component Composite Secondary Endpoint (Nonfatal MI, Nonfatal Ischemic Stroke, Hospitalization for Unstable Angina Requiring Unplanned Coronary Revascularization, or CV Death)

    The 4-component composite secondary endpoints events are nonfatal myocardial infarction, nonfatal ischemic stroke, hospitalization for unstable angina requiring unplanned coronary revascularization, or cardiovascular death

    Time frame: From Baseline to a Median of 3.3 Years

  2. Number of Participants With First Occurrence of the 3-component Composite Endpoint (Nonfatal Myocardial Infarction, Nonfatal Ischemic Stroke, or Cardiovascular Death)

    Number of Participants with First Occurrence of Composite Cardiovascular Events (nonfatal myocardial infarction, nonfatal ischemic stroke, or cardiovascular death)

    Time frame: From Baseline to a Median of 3.3 Years

  3. Number of Participants With First Occurrence of Any Component of the Primary Endpoint or Hospitalization for Heart Failure

    Event is the first occurrence of any component of the composite endpoint of nonfatal myocardial infarction, nonfatal ischemic stroke, coronary revascularization, cardiovascular death, or hospitalization for heart failure

    Time frame: From Baseline to a Median of 3.3 Years

  4. Number of Participants With Occurrence of Any Component of the Primary Endpoint or All-Cause Mortality

    Event is the first occurrence of any component of the composite endpoint of nonfatal myocardial infarction, nonfatal ischemic stroke, coronary revascularization, cardiovascular death, or all-cause mortality.

    Time frame: From Baseline to a Median of 3.3 Years

  5. Total Number of Events of the 4-component Composite Primary Endpoint

    Total number of events for the 4-component composite primary endpoint, counting all occurrences, including multiple events in the same participant. The endpoint events include nonfatal myocardial infarction (MI), nonfatal ischemic stroke, coronary revascularization, and cardiovascular (CV) death.

    Time frame: From Baseline to a Median of 3.3 Years

  6. Number of Participants With First Occurrence of Any New or Worsening Peripheral Artery Disease (PAD)

    Any new or worsening Peripheral artery disease (PAD), defined as incidence of lower extremity revascularization, intermittent claudication, rest pain, lower extremity ischemic ulceration, or major amputation with either ankle-brachial index ≤ 0.9 or other diagnostic testing (eg, toe-brachial index, angiogram, or other imaging study)

    Time frame: From Baseline to a Median of 3.3 Years

  7. Number of Participants With First Occurrence of Nonfatal Myocardial Infarction

    Time frame: From Baseline to a Median of 3.3 Years

  8. Number of Participants With First Occurrence of Nonfatal Ischemic Stroke

    Time frame: From Baseline to a Median of 3.3 Years

  9. Number of Participants With First Occurrence of Coronary Revascularization

    Time frame: From Baseline to a Median of 3.3 Years

  10. Number of Participants With First Occurrence of Cardiovascular Death

    Time frame: From Baseline to a Median of 3.3 Years

  11. Number of Participants With First Occurrence of the 4-component Composite Endpoint by PPAR-α Gene Variant Subgroup (TT, CT, CC)

    Number of participants experiencing their first occurrence of any component of the 4-component composite primary endpoint (nonfatal myocardial infarction, nonfatal ischemic stroke, coronary revascularization, or cardiovascular death), reported as a subgroup analysis by PPAR-α gene variants (TT, CT, CC).

    Time frame: From Baseline to a Median of 3.3 Years

  12. Percent Change From Baseline to Month 4 for Total Cholesterol (TC)

    Time frame: Baseline to Month 4

  13. Percent Change From Baseline to Month 4 for Fasting Triglycerides

    Time frame: Baseline to 4 Months

  14. Percent Change From Baseline to Month 4 for HDL - Cholesterol (HDL-C)

    Time frame: Baseline to Month 4

  15. Percent Change From Baseline to Month 4 for Calculated Non-HDL Cholesterol (Non-HDL-C)

    Time frame: Baseline to Month 4

  16. Percent Change From Baseline to Month 4 for Calculated VLDL Cholesterol

    Time frame: Baseline to Month 4

  17. Percent Change From Baseline to Month 4 for Apolipoprotein A1 (ApoA1)

    Time frame: Baseline to Month 4

  18. Percent Change From Baseline to Month 4 for Apolipoprotein CIII (ApoC3)

    Time frame: Baseline to Month 4

  19. Percent Change From Baseline to Month 4 for Apolipoprotein E (ApoE)

    Time frame: Baseline to Month 4

  20. Percent Change From Baseline to Month 6 for Non-fasting Remnant Cholesterol

    Time frame: Baseline to Month 6

07

Results

Posted Sep 25, 2025

Participant flow

Participant flow — Overall Study
MilestonePemafibratePlacebo
Started52695275
Completed46474674
Not completed622601

Outcome measures

PrimaryNumber of Participants With First Occurrence of 4-component Composite Primary Endpoint (Nonfatal MI, Nonfatal Ischemic Stroke, Coronary Revascularization, or CV Death)

Number of participants experiencing their first occurrence of any component of the 4-component composite primary endpoint, which includes nonfatal myocardial infarction (MI), nonfatal ischemic stroke, coronary revascularization, or cardiovascular (CV) death. Each participant is counted only once, regardless of any subsequent events.

Time frame:
From Baseline to a Median of 3.3 Years
Reported as:
Number · participants
Number of Participants With First Occurrence of 4-component Composite Primary Endpoint (Nonfatal MI, Nonfatal Ischemic Stroke, Coronary Revascularization, or CV Death)
participantsPemafibratePlacebo
Number of Participants With First Occurrence of 4-component Composite Primary Endpoint (Nonfatal MI, Nonfatal Ischemic Stroke, Coronary Revascularization, or CV Death)590570
Statistical analysis
  • Pemafibrate vs Placebo · Hazard ratio (hr): 1.03 · 95% CI 0.92 to 1.16
SecondaryNumber of Participants With First Occurrence of the 4-component Composite Secondary Endpoint (Nonfatal MI, Nonfatal Ischemic Stroke, Hospitalization for Unstable Angina Requiring Unplanned Coronary Revascularization, or CV Death)

The 4-component composite secondary endpoints events are nonfatal myocardial infarction, nonfatal ischemic stroke, hospitalization for unstable angina requiring unplanned coronary revascularization, or cardiovascular death

Time frame:
From Baseline to a Median of 3.3 Years
Reported as:
Number · participants
Number of Participants With First Occurrence of the 4-component Composite Secondary Endpoint (Nonfatal MI, Nonfatal Ischemic Stroke, Hospitalization for Unstable Angina Requiring Unplanned Coronary Revascularization, or CV Death)
participantsPemafibratePlacebo
Number of Participants With First Occurrence of the 4-component Composite Secondary Endpoint (Nonfatal MI, Nonfatal Ischemic Stroke, Hospitalization for Unstable Angina Requiring Unplanned Coronary Revascularization, or CV Death)447427
Statistical analysis
  • Pemafibrate vs Placebo · Hazard ratio (hr): 1.05 · 95% CI 0.92 to 1.20
SecondaryNumber of Participants With First Occurrence of the 3-component Composite Endpoint (Nonfatal Myocardial Infarction, Nonfatal Ischemic Stroke, or Cardiovascular Death)

Number of Participants with First Occurrence of Composite Cardiovascular Events (nonfatal myocardial infarction, nonfatal ischemic stroke, or cardiovascular death)

Time frame:
From Baseline to a Median of 3.3 Years
Reported as:
Number · participants
Number of Participants With First Occurrence of the 3-component Composite Endpoint (Nonfatal Myocardial Infarction, Nonfatal Ischemic Stroke, or Cardiovascular Death)
participantsPemafibratePlacebo
Number of Participants With First Occurrence of the 3-component Composite Endpoint (Nonfatal Myocardial Infarction, Nonfatal Ischemic Stroke, or Cardiovascular Death)396386
Statistical analysis
  • Pemafibrate vs Placebo · Hazard ratio (hr): 1.03 · 95% CI 0.89 to 1.18
SecondaryNumber of Participants With First Occurrence of Any Component of the Primary Endpoint or Hospitalization for Heart Failure

Event is the first occurrence of any component of the composite endpoint of nonfatal myocardial infarction, nonfatal ischemic stroke, coronary revascularization, cardiovascular death, or hospitalization for heart failure

Time frame:
From Baseline to a Median of 3.3 Years
Reported as:
Number · participants
Number of Participants With First Occurrence of Any Component of the Primary Endpoint or Hospitalization for Heart Failure
participantsPemafibratePlacebo
Number of Participants With First Occurrence of Any Component of the Primary Endpoint or Hospitalization for Heart Failure670645
Statistical analysis
  • Pemafibrate vs Placebo · Hazard ratio (hr): 1.04 · 95% CI 0.93 to 1.16
SecondaryNumber of Participants With Occurrence of Any Component of the Primary Endpoint or All-Cause Mortality

Event is the first occurrence of any component of the composite endpoint of nonfatal myocardial infarction, nonfatal ischemic stroke, coronary revascularization, cardiovascular death, or all-cause mortality.

Time frame:
From Baseline to a Median of 3.3 Years
Reported as:
Number · participants
Number of Participants With Occurrence of Any Component of the Primary Endpoint or All-Cause Mortality
participantsPemafibratePlacebo
Number of Participants With Occurrence of Any Component of the Primary Endpoint or All-Cause Mortality830806
Statistical analysis
  • Pemafibrate vs Placebo · Hazard ratio (hr): 1.03 · 95% CI 0.93 to 1.13
SecondaryTotal Number of Events of the 4-component Composite Primary Endpoint

Total number of events for the 4-component composite primary endpoint, counting all occurrences, including multiple events in the same participant. The endpoint events include nonfatal myocardial infarction (MI), nonfatal ischemic stroke, coronary revascularization, and cardiovascular (CV) death.

Time frame:
From Baseline to a Median of 3.3 Years
Reported as:
Number · Events
Total Number of Events of the 4-component Composite Primary Endpoint
EventsPemafibratePlacebo
Total Number of Events of the 4-component Composite Primary Endpoint895892
Statistical analysis
  • Pemafibrate vs Placebo · Event rate ration: 0.99 · 95% CI 0.87 to 1.13
SecondaryNumber of Participants With First Occurrence of Any New or Worsening Peripheral Artery Disease (PAD)

Any new or worsening Peripheral artery disease (PAD), defined as incidence of lower extremity revascularization, intermittent claudication, rest pain, lower extremity ischemic ulceration, or major amputation with either ankle-brachial index ≤ 0.9 or other diagnostic testing (eg, toe-brachial index, angiogram, or other imaging study)

Time frame:
From Baseline to a Median of 3.3 Years
Reported as:
Number · participants
Number of Participants With First Occurrence of Any New or Worsening Peripheral Artery Disease (PAD)
participantsPemafibratePlacebo
Number of Participants With First Occurrence of Any New or Worsening Peripheral Artery Disease (PAD)138159
Statistical analysis
  • Pemafibrate vs Placebo · Hazard ratio (hr): 0.87 · 95% CI 0.69 to 1.09
SecondaryNumber of Participants With First Occurrence of Nonfatal Myocardial Infarction
Time frame:
From Baseline to a Median of 3.3 Years
Reported as:
Number · participants
Number of Participants With First Occurrence of Nonfatal Myocardial Infarction
participantsPemafibratePlacebo
Number of Participants With First Occurrence of Nonfatal Myocardial Infarction210182
Statistical analysis
  • Pemafibrate vs Placebo · Hazard ratio (hr): 1.16 · 95% CI 0.95 to 1.41
SecondaryNumber of Participants With First Occurrence of Nonfatal Ischemic Stroke
Time frame:
From Baseline to a Median of 3.3 Years
Reported as:
Number · participants
Number of Participants With First Occurrence of Nonfatal Ischemic Stroke
participantsPemafibratePlacebo
Number of Participants With First Occurrence of Nonfatal Ischemic Stroke96106
Statistical analysis
  • Pemafibrate vs Placebo · Hazard ratio (hr): 0.90 · 95% CI 0.69 to 1.19
SecondaryNumber of Participants With First Occurrence of Coronary Revascularization
Time frame:
From Baseline to a Median of 3.3 Years
Reported as:
Number · participants
Number of Participants With First Occurrence of Coronary Revascularization
participantsPemafibratePlacebo
Number of Participants With First Occurrence of Coronary Revascularization340347
Statistical analysis
  • Pemafibrate vs Placebo · Hazard ratio (hr): 0.98 · 95% CI 0.84 to 1.14
SecondaryNumber of Participants With First Occurrence of Cardiovascular Death
Time frame:
From Baseline to a Median of 3.3 Years
Reported as:
Number · participants
Number of Participants With First Occurrence of Cardiovascular Death
participantsPemafibratePlacebo
Number of Participants With First Occurrence of Cardiovascular Death145139
Statistical analysis
  • Pemafibrate vs Placebo · Hazard ratio (hr): 1.04 · 95% CI 0.83 to 1.32
SecondaryNumber of Participants With First Occurrence of the 4-component Composite Endpoint by PPAR-α Gene Variant Subgroup (TT, CT, CC)

Number of participants experiencing their first occurrence of any component of the 4-component composite primary endpoint (nonfatal myocardial infarction, nonfatal ischemic stroke, coronary revascularization, or cardiovascular death), reported as a subgroup analysis by PPAR-α gene variants (TT, CT, CC).

Time frame:
From Baseline to a Median of 3.3 Years
Reported as:
Number · Count of Participants
Number of Participants With First Occurrence of the 4-component Composite Endpoint by PPAR-α Gene Variant Subgroup (TT, CT, CC)
Count of ParticipantsPemafibratePlacebo
TT variant114117
CT variant177156
CC variant6365
Statistical analysis
  • Pemafibrate vs Placebo · Hazard ratio (hr): 0.97 · 95% CI 0.75 to 1.26
  • Pemafibrate vs Placebo · Hazard ratio (hr): 1.19 · 95% CI 0.96 to 1.47
  • Pemafibrate vs Placebo · Hazard ratio (hr): 0.98 · 95% CI 0.69 to 1.39
SecondaryPercent Change From Baseline to Month 4 for Total Cholesterol (TC)
Time frame:
Baseline to Month 4
Reported as:
Mean · Percent Change
Percent Change From Baseline to Month 4 for Total Cholesterol (TC)
Percent ChangePemafibratePlacebo
Percent Change From Baseline to Month 4 for Total Cholesterol (TC)5.235 ± 23.76834.562 ± 23.9991
Statistical analysis
  • Pemafibrate vs Placebo · ANCOVA · p = 0.13496
SecondaryPercent Change From Baseline to Month 4 for Fasting Triglycerides
Time frame:
Baseline to 4 Months
Reported as:
Mean · Percent Change
Percent Change From Baseline to Month 4 for Fasting Triglycerides
Percent ChangePemafibratePlacebo
Percent Change From Baseline to Month 4 for Fasting Triglycerides-23.860 ± 49.22892.593 ± 60.6399
Statistical analysis
  • Pemafibrate vs Placebo · ANCOVA · p = <0.001
SecondaryPercent Change From Baseline to Month 4 for HDL - Cholesterol (HDL-C)
Time frame:
Baseline to Month 4
Reported as:
Mean · Percent Change
Percent Change From Baseline to Month 4 for HDL - Cholesterol (HDL-C)
Percent ChangePemafibratePlacebo
Percent Change From Baseline to Month 4 for HDL - Cholesterol (HDL-C)10.856 ± 24.74076.004 ± 21.7838
Statistical analysis
  • Pemafibrate vs Placebo · ANCOVA · p = <0.001
SecondaryPercent Change From Baseline to Month 4 for Calculated Non-HDL Cholesterol (Non-HDL-C)
Time frame:
Baseline to Month 4
Reported as:
Mean · Percent Change
Percent Change From Baseline to Month 4 for Calculated Non-HDL Cholesterol (Non-HDL-C)
Percent ChangePemafibratePlacebo
Percent Change From Baseline to Month 4 for Calculated Non-HDL Cholesterol (Non-HDL-C)5.219 ± 31.92625.502 ± 31.9739
Statistical analysis
  • Pemafibrate vs Placebo · ANCOVA · p = 0.96689
SecondaryPercent Change From Baseline to Month 4 for Calculated VLDL Cholesterol
Time frame:
Baseline to Month 4
Reported as:
Mean · Percent Change
Percent Change From Baseline to Month 4 for Calculated VLDL Cholesterol
Percent ChangePemafibratePlacebo
Percent Change From Baseline to Month 4 for Calculated VLDL Cholesterol-22.788 ± 32.5741-1.601 ± 36.4352
Statistical analysis
  • Pemafibrate vs Placebo · ANCOVA · p = <0.001
SecondaryPercent Change From Baseline to Month 4 for Apolipoprotein A1 (ApoA1)
Time frame:
Baseline to Month 4
Reported as:
Mean · Percent Change
Percent Change From Baseline to Month 4 for Apolipoprotein A1 (ApoA1)
Percent ChangePemafibratePlacebo
Percent Change From Baseline to Month 4 for Apolipoprotein A1 (ApoA1)4.878 ± 19.37493.956 ± 18.5293
Statistical analysis
  • Pemafibrate vs Placebo · ANCOVA · p = 0.09178
SecondaryPercent Change From Baseline to Month 4 for Apolipoprotein CIII (ApoC3)
Time frame:
Baseline to Month 4
Reported as:
Mean · Percent Change
Percent Change From Baseline to Month 4 for Apolipoprotein CIII (ApoC3)
Percent ChangePemafibratePlacebo
Percent Change From Baseline to Month 4 for Apolipoprotein CIII (ApoC3)-23.397 ± 31.57564.861 ± 56.0921
Statistical analysis
  • Pemafibrate vs Placebo · ANCOVA · p = <0.001
SecondaryPercent Change From Baseline to Month 4 for Apolipoprotein E (ApoE)
Time frame:
Baseline to Month 4
Reported as:
Mean · Percent Change
Percent Change From Baseline to Month 4 for Apolipoprotein E (ApoE)
Percent ChangePemafibratePlacebo
Percent Change From Baseline to Month 4 for Apolipoprotein E (ApoE)-6.5201 ± 30.89475-0.5209 ± 31.79989
Statistical analysis
  • Pemafibrate vs Placebo · ANCOVA · p = <0.001
SecondaryPercent Change From Baseline to Month 6 for Non-fasting Remnant Cholesterol
Time frame:
Baseline to Month 6
Reported as:
Mean · Percent Change
Percent Change From Baseline to Month 6 for Non-fasting Remnant Cholesterol
Percent ChangePemafibratePlacebo
Percent Change From Baseline to Month 6 for Non-fasting Remnant Cholesterol-21.27 ± 46.50610.60 ± 54.029
Statistical analysis
  • Pemafibrate vs Placebo · ANCOVA · p = <0.001

Adverse events

Collected over From Baseline to a Median of 3.3 Years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemafibrate308/5,264 (5.9%)1,715/5,264 (32.6%)2,817/5,264 (53.5%)
Placebo310/5,274 (5.9%)1,663/5,274 (31.5%)2,883/5,274 (54.7%)
Most frequent serious events
Showing 10 of 1,184
Most frequent serious events
EventPemafibratePlacebo
Angina unstableCardiac disorders97/526495/5274
Acute myocardial infarctionCardiac disorders97/526493/5274
COVID-19 pneumoniaInfections and infestations95/526491/5274
PneumoniaInfections and infestations82/526487/5274
Cardiac failureCardiac disorders84/526468/5274
Atrial fibrillationCardiac disorders53/526473/5274
Angina pectorisCardiac disorders69/526459/5274
Coronary artery diseaseCardiac disorders66/526459/5274
Acute kidney injuryRenal and urinary disorders66/526442/5274
Peripheral arterial occlusive diseaseVascular disorders37/526460/5274
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPemafibratePlacebo
Diabetes mellitusMetabolism and nutrition disorders738/5264677/5274
HypertensionVascular disorders683/5264664/5274
Urinary tract infectionInfections and infestations417/5264461/5274
ArthralgiaMusculoskeletal and connective tissue disorders417/5264454/5274
COVID-19Infections and infestations361/5264377/5274
NasopharyngitisInfections and infestations358/5264354/5274
Diabetic nephropathyRenal and urinary disorders358/5264343/5274
Back painMusculoskeletal and connective tissue disorders311/5264355/5274
DiarrhoeaGastrointestinal disorders308/5264343/5274
InfluenzaInfections and infestations251/5264290/5274

Baseline characteristics

The Intent to treat (ITT) population included all randomized subjects who received at least 1 dose of study treatment without GCP deviations.

Age, Continuous
Age, Continuous(Years)PemafibratePlaceboTotal
Mean63.28 ± 8.52463.56 ± 8.41163.42 ± 8.468
Sex: Female, Male
Sex: Female, Male(Participants)PemafibratePlaceboTotal
Female144314482891
Male379738097606
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PemafibratePlaceboTotal
Hispanic or Latino101410072021
Not Hispanic or Latino418742138400
Unknown or Not Reported393776
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PemafibratePlaceboTotal
White448445499033
Black or African American134136270
American Indian or Alaska Native7376149
Asian Indian9780177
Bangladeshi033
Chinese314
Filipino257
Japanese162146308
Korean000
Pakistani13619
Vietnamese101
Other Asian131023
Native Hawaiian000
Guamanian or Chamorro000
Samoan000
Other Pacific Islander101
Multiracial293261
Other208201409
Declined201232
Cardiovascular Diseases and Risk Factors at Baseline
Cardiovascular Diseases and Risk Factors at Baseline(Participants)PemafibratePlaceboTotal
Statin Status — No220219439
Statin Status — Yes5020503810058
Established CV Disease — No169517133408
Established CV Disease — Yes354535447089
08

Study locations

888 sites
  • Synexus Clinical Research US, Inc.
    Birmingham, Alabama 35211, United States
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • VA Medical Center - Birmingham
    Birmingham, Alabama 35233, United States
  • Alabama Clinical Therapeutics, LLC
    Birmingham, Alabama 35235, United States
  • Fundamental Research, LLC
    Gulf Shores, Alabama 36542, United States
  • Mobile Heart Specialists, PC
    Mobile, Alabama 36608, United States
  • Terence T. Hart, MD
    Tuscumbia, Alabama 35674, United States
  • Synexus Clinical Research US, Inc.
    Chandler, Arizona 85224-6279, United States
  • Synexus Clinical Research US, Inc.
    Mesa, Arizona 85206, United States
  • Arizona Arthritis & Rheumatology Research, PLLC
    Peoria, Arizona 85381, United States
  • Phoenix Veterans Adminstration Health Care System
    Phoenix, Arizona 85012, United States
  • Synexus Clinical Research US, Inc.
    Phoenix, Arizona 85050, United States
  • Clinical Research Institute of Arizona, LLC
    Surprise, Arizona 85374, United States
  • Synexus Clinical Research US, Inc.
    Tucson, Arizona 85712, United States
  • Eclipse Clinical Research
    Tucson, Arizona 85745, United States
  • Central Arkansas Veterans Healthcare System
    Little Rock, Arkansas 72205, United States
  • Clinical Research Alliance, Inc
    Alhambra, California 91801, United States
  • Aurora Care Clinic
    Costa Mesa, California 92627, United States
  • AMCR Institute, Inc.
    Escondido, California 92025, United States
  • National Institute of Clinical Research
    Huntington Beach, California 92648-1717, United States
  • VA Loma Linda Healthcare System
    Loma Linda, California 92354, United States
  • VA Long Beach Healthcare System
    Long Beach, California 90822, United States
  • Eastside Clinical Research Associates
    Los Angeles, California 90022, United States
  • VA Greater Los Angeles Healthcare System
    Los Angeles, California 90073, United States
  • Richard S. Cherlin, MD
    Los Gatos, California 95032, United States
  • Northridge Clinical Research Inc.
    Northridge, California 91324, United States
  • Palo Alto Division
    Palo Alto, California 94304, United States
  • Huntington Hospital - Research Department
    Pasadena, California 91105, United States
  • Rancho Cucamonga Clinical Research
    Rancho Cucamonga, California 91730, United States
  • MD Strategies Research Centers
    San Diego, California 92119, United States
  • Alex Harrison, MD Inc.
    Santa Maria, California 93454, United States
  • Santa Rosa Cardiology Medical Group, Inc.
    Santa Rosa, California 95404, United States
  • Blue Coast Cardiology
    Vista, California 92083, United States
  • Lynn Institute of Denver
    Aurora, Colorado 80012, United States
  • New West Physicians, PC
    Golden, Colorado 80401, United States
  • Southwest Family Medicine
    Littleton, Colorado 80127, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • VA Connecticut Healthcare Sys
    West Haven, Connecticut 06516-2770, United States
  • Cardiology Physicians, PA
    Newark, Delaware 19713, United States
  • Bay Pines VA Healthcare System
    Bay Pines, Florida 33744, United States
  • Meridien Research
    Bradenton, Florida 34201, United States
  • Clinical Research Of Brandon, LLC
    Brandon, Florida 33511, United States
  • Clearwater Cardiovascular Consultants
    Clearwater, Florida 33756, United States
  • Daytona Heart Group
    Daytona Beach, Florida 32114, United States
  • Cohen Medical Research Associates, LLC
    Delray Beach, Florida 33446, United States
  • Malcom Randall VA Medical Center
    Gainesville, Florida 32608, United States
  • Pines Clinical Research, Inc.
    Hollywood, Florida 33024, United States
  • Homestead Cardiac & Vein Center
    Homestead, Florida 33030, United States
  • Westside Center for Clinical Research
    Jacksonville, Florida 32205, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Health Awareness, Inc.
    Jupiter, Florida 33458, United States
  • Meridien Research
    Lakeland, Florida 33805, United States
  • Clearwater Cardiovascular & Interventional Consultants
    Largo, Florida 33777, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Advanced Medical Research Institute
    Miami, Florida 33174, United States
  • Ocala Research Institute, Inc.
    Ocala, Florida 34471, United States
  • Morgan Medical Management & Consultants Inc.
    Ocala, Florida 34474, United States
  • Endocrine Associates of Florida
    Ocoee, Florida 34761, United States
  • Research Physicians Network Alliance
    Orlando, Florida 32803, United States
  • Andres Patron, D.O., P.A
    Pembroke Pines, Florida 33026, United States
  • DBC Research, Corp
    Pembroke Pines, Florida 33029, United States
  • Langhorne Cardiology Consultants, Inc.
    Pensacola, Florida 32501, United States
  • Clearwater Cardiovascular Consultants
    Safety Harbor, Florida 34695, United States
  • Professional Health Care of Pinellas
    St. Petersburg, Florida 33713, United States
  • James A. Haley VA Medical Center
    Tampa, Florida 33612, United States
  • Clinical Research of Central Florida
    Winter Haven, Florida 33880, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Atlanta Heart Specialists, LLC
    Cumming, Georgia 30041, United States
  • VA Medical Center - Atlanta
    Decatur, Georgia 30033, United States
  • Alta Pharmaceutical Research Center, Inc.
    Dunwoody, Georgia 30338, United States
  • Atlanta Heart Specialists, LLC
    Tucker, Georgia 30084, United States
  • Christie Clinic, LLC
    Champaign, Illinois 61822, United States
  • Apex Medical Research, AMR, Inc.
    Chicago, Illinois 60607, United States
  • Clinical Investigation Specialists, Inc.
    Gurnee, Illinois 60031, United States
  • Edward Hines Jr. VA Hospital
    Hines, Illinois 60141, United States
  • Advocate Health and Hospitals Corp
    Normal, Illinois 61761, United States
  • Captain James A. Lovell Federal Health Care Center
    North Chicago, Illinois 60064, United States
  • Specialty Physicians of Illinois
    Olympia Fields, Illinois 60461, United States
  • Community Hospital of Anderson and Madison County, Inc.
    Anderson, Indiana 46011, United States
  • Synexus Clinical Research US, Inc.
    Evansville, Indiana 47714, United States
  • Deaconess Clinic
    Evansville, Indiana 47725, United States
  • VA Medical Center - Indianapolis
    Indianapolis, Indiana 46202, United States
  • Cardiovascular Research of Northwest Indiana, LLC
    Munster, Indiana 46321, United States
  • Buynak Clinical Research
    Valparaiso, Indiana 46383, United States
  • West Broadway Clinic
    Council Bluffs, Iowa 51501, United States
  • Iowa Diabetes and Endocrinology Research Center, PLC
    Des Moines, Iowa 50314, United States
  • The Iowa Clinic, PC
    West Des Moines, Iowa 50266, United States
  • University of Kansas Medical Center Research Institute, Inc.
    Kansas City, Kansas 66160, United States
  • VA Eastern Kansas Health Care
    Leavenworth, Kansas 66048, United States
  • The Research Group of Lexington, LLC
    Lexington, Kentucky 40503, United States
  • Robley Rex VA Medical Center
    Louisville, Kentucky 40206, United States
  • Cambridge Medical Trials
    Alexandria, Louisiana 71301, United States
  • Cardiovascular Associates Research, LLC
    Covington, Louisiana 70433, United States
  • Centex Studies Inc.
    Lake Charles, Louisiana 70601, United States
  • Overton Brooks VA Medical Center
    Shreveport, Louisiana 71101, United States
  • Southern Maine Health Care
    Biddeford, Maine 04005, United States
  • Baltimore VA medical centre
    Baltimore, Maryland 21201, United States
  • University of Maryland School of Medicine
    Baltimore, Maryland 21201, United States
  • Maryland Cardiovascular Specialists
    Baltimore, Maryland 21229, United States
  • Medstar Health Research Institute
    Hyattsville, Maryland 20782, United States

Showing the first 100 of 888 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Pall D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. PubMed 36342113 ↗
  • Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, Ginsberg H, Hiatt WR, Ishibashi S, Koenig W, Nordestgaard BG, Fruchart JC, Libby P, Ridker PM. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 2018 Dec;206:80-93. doi: 10.1016/j.ahj.2018.09.011. Epub 2018 Sep 29. PubMed 30342298 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Jul 2022, 64 months.

Results were first posted in Sep 2025, 3 years 1 month after primary completion. A results delay was requested in Jul 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2017
First posted
Mar 7, 2017
StartActual
Mar 23, 2017
Primary completionActual
Jul 27, 2022
CompletionActual
Jul 27, 2022
Results delay requested
Jul 11, 2023
Results first posted
Sep 25, 2025
Last update
Sep 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03071692
Responsible party
Sponsor
First posted
Mar 7, 2017
Start date
Mar 23, 2017
Primary completion
Jul 27, 2022
Completion
Jul 27, 2022
Results posted
Sep 25, 2025
Last update
Sep 25, 2025

Study contacts

Paul Ridker, MD
study director · CCVDP & The Brigham and Women's Hospital
Aruna Pradhan, MD
study director · CCVDP & The Brigham and Women's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemafibrate

Start the discussion